TRINETRA › Sectors › Healthcare
Aarti Pharmalabs Limited (AARTIPHARM) — share price, P/E and fundamentals
Aarti Pharmalabs Limited (NSE: AARTIPHARM) closed at ₹872.70 on 30 Oct 2026, +4.7% over one year, against a 52-week range of ₹585.00 – ₹1,002.40.
In the quarter ended 30 Sept 2026 (consolidated, filed 28 Oct 2026) it reported revenue of ₹610 cr and net profit of ₹69 cr, a 11.3% net margin; revenue grew 45.9% and profit grew 124.0% year on year.
On four consecutive filed quarters its trailing P/E is 31.3; since 12 May 2025 its own P/E has ranged from 22.6 to 41.5 (median 29.7), and today's reading is higher than 66% of those 364 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 12.2%, ROCE 15.6%, debt-to-equity 0.37, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 32% of 63 sector peers; PBT margin higher than 30% of 63 sector peers; ROE higher than 43% of 63 sector peers.
Key figures
| Last close | ₹872.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.6% / +25.9% / +4.7% |
| 52-week low – high | ₹585.00 – ₹1,002.40 |
| Market capitalisation | ₹7,914 cr |
| Trailing P/E | 31.3 |
| Price / book | 3.51 |
| EV / EBITDA | 17.8 |
| Earnings yield | 3.2% |
| TTM EPS | ₹27.85 |
| TTM net profit | ₹253 cr |
| Quarter revenue | ₹610 cr |
| Quarter net profit | ₹69 cr |
| Net margin | 11.3% |
| Revenue growth (YoY) | +45.9% |
| Profit growth (YoY) | +124.0% |
| Return on equity | 12.2% |
| ROCE | 15.6% |
| Debt / equity | 0.37 |
| Current ratio | 1.40 |
| Free cash flow | ₹-93 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹43.0 cr |
Against Healthcare peers
| Metric | AARTIPHARM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 11.29 | 12.89 | 32 |
| PBT margin | 14.43 | 17.68 | 30 |
| ROE | 12.23 | 13.87 | 43 |
| ROCE | 15.58 | 17.26 | 40 |
| Debt / equity | 0.37 | 0.11 | 77 |
| FCF margin | -8.13 | 2.08 | 21 |
| Cash conversion | 0.20 | 1.25 | 5 |
| Trailing P/E | 31.33 | 43.26 | 24 |
Questions
What is the P/E ratio of Aarti Pharmalabs Limited?
Aarti Pharmalabs Limited's trailing P/E is 31.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 12 May 2025 its P/E has ranged 22.6–41.5.
What were Aarti Pharmalabs Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Aarti Pharmalabs Limited reported revenue of ₹610 cr and net profit of ₹69 cr (consolidated), filed with the exchange on 28 Oct 2026.
What is Aarti Pharmalabs Limited's ROE?
Return on equity is 12.2% based on the balance sheet dated 30 Sept 2026.
Does Aarti Pharmalabs Limited have debt?
Debt-to-equity is 0.37 on the balance sheet dated 30 Sept 2026.
What is AARTIPHARM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, AARTIPHARM traded between ₹585.00 and ₹1,002.40.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.